Journal of Clinical Oncology, Vol 11, 1245-1252, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

P Fumoleau, FM Delgado, T Delozier, A Monnier, MA Gil Delgado, P Kerbrat, E Garcia-Giralt, R Keiling, M Namer and MT Closon
Pierre Fabre Research Centre, Boulogne, France.

PURPOSE: This study investigated the therapeutic effects of single- agent intravenous (IV) weekly Navelbine (vinorelbine or 5'-nor-anhydro- vinblastine; Pierre Fabre Medicament, Boulogne, France), a semisynthetic vinca alkaloid, in women who had received no prior chemotherapy for locally advanced or metastatic breast cancer. PATIENTS AND METHODS: One hundred fifty-seven patients with assessable advanced or metastatic breast cancer who had received no prior chemotherapy were entered onto the study. They were stratified into five groups according to the main assessable tumor target: lung, liver, lymph nodes, skin, and others. One hundred forty-five patients were assessable for toxicity and response using World Health Organization (WHO) criteria; the 12 patients who were not evaluated were excluded because they were found not to meet the eligibility criteria. Navelbine was administered as a weekly 30-mg/m2 short IV infusion, and treatment was continued until disease progression. RESULTS: The overall response rate (WHO criteria) was 41% (complete response [CR], 7%; partial response [PR], 34%; 95% confidence interval [CI], 33% to 49%). In addition, 30% of the patients had stable disease. The response rate according to target was lymph nodes (28 of 42), 67%; liver (nine of 39), 23%; lung (10 of 30), 33%; skin (21 of 30), 70%; primary tumor (10 of 16), 56%; and bone (three of 10), 30%. The median time to treatment failure was 6 months and the median survival was 18 months. A total of 1,673 cycles were given to 145 eligible patients. At least one episode of WHO grade 3 or 4 granulocytopenia was seen in 72% of the patients. Nausea and/or vomiting, anemia, and/or thrombocytopenia were seen in less than 1% of cycles. Other side effects were rare, and additional toxicities were documented in the following proportions of patients: grade 2 to 3 alopecia, 8%; infectious episodes, 6%; and peripheral neuropathy, 3%. CONCLUSION: Our data confirm that Navelbine has major single-agent antitumor activity as front-line therapy in advanced breast cancer. Given its excellent tolerance profile and low toxicity, it should be considered for inclusion in first-line combination chemotherapy regimens.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith, E. Tan-Chiu, J. Wright, A. R. Tan, N. A. DaCosta, E. Chuang, et al. Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., June 20, 2009; 27(18): 2954 - 2961. [Abstract] [Full Text] [PDF]

				A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M. Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist, June 1, 2006; 11(6): 563 - 573. [Abstract] [Full Text] [PDF]

				F. Nole, C. Catania, G. Sanna, K. Imadalou, E. Munzone, L. Adamoli, B. Longerey, G. Blanchot, and A. Goldhirsch Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer Ann. Onc., February 1, 2006; 17(2): 322 - 329. [Abstract] [Full Text] [PDF]

				S. Chua, I. E. Smith, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E. R. O'Brien, S. R. Ebbs, A. Hong, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) Ann. Onc., September 1, 2005; 16(9): 1435 - 1441. [Abstract] [Full Text] [PDF]

				M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al. Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315. [Abstract] [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				A. Welt, G. von Minckwitz, C. Oberhoff, D. Borquez, R. Schleucher, S. Loibl, A. Harstrick, M. Kaufmann, S. Seeber, and U. Vanhoefer Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer Ann. Onc., January 1, 2005; 16(1): 64 - 69. [Abstract] [Full Text] [PDF]

				B. Ejlertsen, H. T. Mouridsen, S. T. Langkjer, J. Andersen, J. Sjostrom, and M. Kjaer Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403) J. Clin. Oncol., June 15, 2004; 22(12): 2313 - 2320. [Abstract] [Full Text] [PDF]

				M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]

				K. Yoh, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, and Y. Nishiwaki High Body Mass Index Correlates with Increased Risk of Venous Irritation by Vinorelbine Infusion Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 206 - 209. [Abstract] [Full Text] [PDF]

				Y. Suzuki, Y. Tokuda, Y. Saito, M. Ohta, and T. Tajima Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 514 - 517. [Abstract] [Full Text] [PDF]

				G. Freyer, T. Delozier, M. Lichinister, D. Gedouin, P. Bougnoux, P. His, K. Imadalou, and V. Trillet-Lenoir Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy J. Clin. Oncol., January 1, 2003; 21(1): 35 - 40. [Abstract] [Full Text] [PDF]

				G. Mustacchi, M. Muggia, S. Milani, R. Ceccherini, M. L. Leita, and C. Dellach A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer Ann. Onc., November 1, 2002; 13(11): 1730 - 1736. [Abstract] [Full Text] [PDF]

				M. Jahanzeb, J. E. Mortimer, F. Yunus, D. H. Irwin, J. Speyer, A. J. Koletsky, P. Klein, T. Sabir, and L. Kronish Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer Oncologist, October 1, 2002; 7(5): 410 - 417. [Abstract] [Full Text] [PDF]

				I. Van Praagh, H. Cure, B. Leduc, S. Charrier, G. Le Bouedec, J.-L. Achard, J.-P. Ferriere, V. Feillel, M. de Latour, J. Dauplat, et al. Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer Oncologist, October 1, 2002; 7(5): 418 - 423. [Abstract] [Full Text] [PDF]

				P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al. First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694. [Abstract] [Full Text] [PDF]

				M. Pawlicki, J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, and P. Tomzak A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma Oncologist, June 1, 2002; 7(3): 205 - 209. [Abstract] [Full Text] [PDF]

				G. P. Stathopoulos, S. K. Rigatos, N. Pergantas, D. Tsavdarides, I. Athanasiadis, N. A. Malamos, and J. G. Stathopoulos Phase II Trial of Biweekly Administration of Vinorelbine and Gemcitabine in Pretreated Advanced Breast Cancer J. Clin. Oncol., January 1, 2002; 20(1): 37 - 41. [Abstract] [Full Text] [PDF]

				J. Abrahamova, M. Wagnerova, E. Kubala, V. Malec, E. Simova, I. Sirakova, E. Pavlikova, D. Machova, I. Kocak, I. Pavlikova, et al. Vinorelbine, Epirubicin, and Methotrexate (VEM) as Primary Treatment in Locally Advanced Breast Cancer Oncologist, August 1, 2001; 6(4): 347 - 352. [Abstract] [Full Text] [PDF]

				H. S. Hochster, C. L. Vogel, S. L. Burman, and R. White Activity and Safety of Vinorelbine Combined with Doxorubicin or Fluorouracil as First-Line Therapy in Advanced Breast Cancer: A Stratified Phase II Study Oncologist, June 1, 2001; 6(3): 269 - 277. [Abstract] [Full Text] [PDF]

				H. J. Burstein, I. Kuter, S. M. Campos, R. S. Gelman, L. Tribou, L. M. Parker, J. Manola, J. Younger, U. Matulonis, C. A. Bunnell, et al. Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2722 - 2730. [Abstract] [Full Text] [PDF]

				J. P. C. Steele, J. Shamash, M. T. Evans, N. H. Gower, M. D. Tischkowitz, and R. M. Rudd Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., December 1, 2000; 18(23): 3912 - 3917. [Abstract] [Full Text] [PDF]

				A. Berruti, P. Sperone, A. Bottini, G. Gorzegno, V. Lorusso, A. Brunelli, M. Botta, M. Tampellini, M. Donadio, S. Mancarella, et al. Phase II Study of Vinorelbine With Protracted Fluorouracil Infusion as a Second- or Third-Line Approach for Advanced Breast Cancer Patients Previously Treated With Anthracyclines J. Clin. Oncol., October 19, 2000; 18(19): 3370 - 3377. [Abstract] [Full Text] [PDF]

				G. Perez-Manga, A. Lluch, E. Alba, J. A. Moreno-Nogueira, M. Palomero, J. Garcia-Conde, D. Khayat, and N. Rivelles Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial J. Clin. Oncol., July 1, 2000; 18(13): 2545 - 2552. [Abstract] [Full Text] [PDF]

				A. Gauvin, F. Pinguet, S. Culine, C. Astre, R. Gomeni, and F. Bressolle Bayesian Estimate of Vinorelbine Pharmacokinetic Parameters in Elderly Patients with Advanced Metastatic Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2690 - 2695. [Abstract] [Full Text]

				I. E. Smith, S. R. D. Johnston, M. E. R. O'Brien, T. F. Hickish, R. H. de Boer, A. Norton, D. T. Cirkel, and C. M. Barton Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study J. Clin. Oncol., June 12, 2000; 18(12): 2378 - 2384. [Abstract] [Full Text] [PDF]

				B. Norris, K. I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, et al. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol., June 12, 2000; 18(12): 2385 - 2394. [Abstract] [Full Text] [PDF]

				J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				C. L. Vogel and J.-M. Nabholtz Monotherapy of Metastatic Breast Cancer: A Review of Newer Agents Oncologist, February 1, 1999; 4(1): 17 - 33. [Abstract] [Full Text]

				L. R. Acuna, M. Langhi, J. Perez, J. R. Acuna, M. Machiavelli, J. Lacava, C. Vallejo, A. Romero, H. Fasce, E. Ortiz, et al. Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer J. Clin. Oncol., January 1, 1999; 17(1): 74 - 74. [Abstract] [Full Text] [PDF]